1.Date of occurrence of the event: 2022/08/17
2.Company name: Lotus Pharmaceutical Co., Ltd.
3.Relationship with the Company (please enter "the company itself" or
"subsidiaries"): the company itself
4.Reciprocal shareholding percentage: NA
5.Name of the reporting media: page C6, Economic
6.Content of the report: The new article states that Lotus's oncology product
is ready for Japan market.
7.Cause of occurrence: The Company does not publish any financial forecasts
to the public. The actual financial results and operational updates are
announced periodically on MOPS as per the relevant regulations. The
estimated figures stated in the news article are at the third parties'
discretion. Please refer to the Company's official announcements on MOPS
for all the financial-related information.
8.Countermeasures: To announcement material information for clarification.
9.Any other matters that need to be specified: Please refer to MOPS for
the Company's official announcements.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Lotus Pharmaceutical Co. Ltd. published this content on 17 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 August 2022 03:33:05 UTC.
Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.
LOTUS PHARMACEUTICAL CO., LTD. 
